132
Views
0
CrossRef citations to date
0
Altmetric
Original Research

ITPA:c.94C>A and NUDT15:c.415C>T Polymorphisms and Their Relation to Mercaptopurine-Related Myelotoxicity in Childhood Leukemia in Thailand

ORCID Icon, ORCID Icon, ORCID Icon, , , & ORCID Icon show all
Pages 341-351 | Published online: 28 Jul 2021

References

  • Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
  • Song TY, Lee SH, Kim G, Baek HJ, Hwang TJ, Kook H. Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia. Blood Res. 2018;53(1):25–34. doi:10.5045/br.2018.53.1.25
  • Shamoon RP, Ali MD, Shabila NP. Overview and outcome of Hodgkin’s lymphoma: experience of a single developing country’s oncology centre. PLoS One. 2018;13(4):e0195629. doi:10.1371/journal.pone.0195629
  • Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524–2539. doi:10.3324/haematol.2020.247031
  • Fu Y, Wang H, Zhai X, et al. Improved outcome of newly diagnosed childhood mature B-cell lymphoma/leukemia with high tumor burden treated with BFM95-based protocol combining rituximab: a report from Shanghai, China. J Pediatr Hematol Oncol. 2019;41(3):170–174. doi:10.1097/MPH.0000000000001419
  • Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. Lancet Oncol. 2003;4(10):595–604. doi:10.1016/S1470-2045(03)01218-X
  • Rusu RA, Sirbu D, Curseu D, et al. Chemotherapy-related infectious complications in patients with Hematologic malignancies. J Res Med Sci. 2018;23:68. doi:10.4103/jrms.JRMS_960_17
  • Nelson JA, Carpenter JW, Rose LM, Adamson DJ. Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res. 1975;35(10):2872–2878.
  • Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol. 1993;15(1):80–86. doi:10.1097/00043426-199302000-00010
  • Ma XL, Wang B, Guo HY, et al. [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi. 2010;48(4):289–292. [Chinese].
  • Albayrak M, Konyssova U, Kaya Z, et al. Thiopurine methyltransferase polymorphisms and mercaptopurine tolerance in Turkish children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2011;68(5):1155–1159. doi:10.1007/s00280-011-1599-7
  • Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol. 2012;68(9):1233–1242. doi:10.1007/s00228-012-1251-4
  • Hiratsuka M, Inoue T, Omori F, Agatsuma Y, Mizugaki M. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat Res. 2000;448(1):91–95. doi:10.1016/S0027-5107(00)00004-X
  • Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9(1):37–42. doi:10.1097/00008571-199902000-00006
  • Chang JG, Lee LS, Chen CM, et al. Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics. 2002;12(3):191–195. doi:10.1097/00008571-200204000-00003
  • Zhou H, Li L, Yang P, et al. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer. 2018;18(1):516. doi:10.1186/s12885-018-4398-2
  • Maeda T, Sumi S, Ueta A, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab. 2005;85(4):271–279. doi:10.1016/j.ymgme.2005.03.011
  • Khera S, Trehan A, Bhatia P, Singh M, Bansal D, Varma N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2019;83(2):341–348. doi:10.1007/s00280-018-3732-3
  • Gerbek T, Ebbesen M, Nersting J, Frandsen TL, Appell ML, Schmiegelow K. Role of TPMT and ITPA variants in mercaptopurine disposition. Cancer Chemother Pharmacol. 2018;81(3):579–586. doi:10.1007/s00280-018-3525-8
  • Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet. 2002;47(11):620–622. doi:10.1007/s100380200095
  • Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–373. doi:10.1038/ng.3508
  • Lu DY, Lu TR, Xu B, Ding J. Pharmacogenetics of cancer therapy: breakthroughs from beyond? Future Sci OA. 2015;1(4):FSO80. doi:10.4155/fso.15.80
  • Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2001;1(2):99–108. doi:10.1038/35101056
  • Erichsen HC, Chanock SJ. SNPs in cancer research and treatment. Br J Cancer. 2004;90(4):747–751. doi:10.1038/sj.bjc.6601574
  • Moradveisi B, Muwakkit S, Zamani F, Ghaderi E, Mohammadi E, Zgheib NK. ITPA, TPMT, and NUDT15 genetic polymorphisms predict 6-mercaptopurine toxicity in middle eastern children with acute lymphoblastic leukemia. Front Pharmacol. 2019;10:916. doi:10.3389/fphar.2019.00916
  • Singh M, Bhatia P, Khera S, Trehan A. Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia. Leuk Res. 2017;62:17–22. doi:10.1016/j.leukres.2017.09.012
  • Stocco G, Crews KR, Evans WE. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf. 2010;9(1):23–37. doi:10.1517/14740330903426151
  • Wahlund M, Nilsson A, Kahlin AZ, et al. The role of TPMT, ITPA, and NUDT15 variants during mercaptopurine treatment of Swedish pediatric patients with acute lymphoblastic leukemia. J Pediatr. 2020;216:150–7 e1. doi:10.1016/j.jpeds.2019.09.024
  • Liang DC, Yang CP, Liu HC, et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):536–539. doi:10.1038/tpj.2015.75
  • Zhu X, Wang XD, Chao K, et al. NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn’s disease. Aliment Pharmacol Ther. 2016;44(9):967–975. doi:10.1111/apt.13796
  • Roberts RL, Barclay ML. Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics. 2015;16(8):891–903. doi:10.2217/pgs.15.29
  • Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2015;171(1):109–115. doi:10.1111/bjh.13518